Arteaga-Gómez AC, Delgado-Amador DE, Medina-Jiménez V, Castillo-Luna R

Language: Spanish
References: 15
Page: 504-509
PDF size: 172.78 Kb.

ABSTRACT

Objetivo: Describe the approach, management and monitoring of patients with cervical intraepithelial neoplasia (NIC) 3 and in situ carcinoma during pregnancy, its evolution and perinatal outcomes.
Material y Métodos: We made a retrospective study of cases from January 2009 to December 2014 in women of the National Institute of Perinatology . We included patients who were diagnosed with cervical intraepithelial neoplasia 3 during pregnancy, with complete file and that received medical consultation of the oncology and obstetrics service since their admission to the hospital for prenatal control until de resolution of pregnancy and oncological definitive treatment.
Resultados: During the study period, 6 cases of pregnant patients where diagnosed with CIN 3, after cervical cytology was taken, a cervical biopsy was performed without complications secondary to this procedure; the histopathological diagnosis was: In situ epidermoid carcinoma in 3 patients and Cervical Intraepithelial Neoplasia in the other 3. All patients were treated with a Multidisciplinary approach. None of the patients presented obstetric or neonatal complications; At the end of the puerperium, follow-up was continued,the mean follow-up after the definitive treatment was 2 years.
Conclusions: The timely diagnosis of precursor lesions of CACU is indispensable, in turn, is not related to adverse perinatal outcomes derived from the approach and timely screening.

REFERENCES

1. http://globocan.iarc.fr/Default.aspx

2. Instituto Nacional de Estadística y Geografía. Regiones Socioeconómicas de México. Disponible en: http://sc.inegi. org.mx/niveles/datosnbi/reg_soc_mexico.pdf.

3. Arteaga-Gómez A, et al. Tratamiento del cáncer cervicouterino en situaciones especiales. Gaceta Mexicana de Oncología 2014; 13(SUPL 4):91-97.

4. Brown D, et al. Special Situations: Abnormal Cervical Cytology During Pregnancy. Clin Obstet Gynecol 2005;48(1):178-185.

5. Silva C, Chung F. Pregnancy and Cancer. Reproductive health and cancer in adolescents and young adults 2012;89-101.

6. Santesso N, et al. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and –treat strategies to prevent cervical cancer. Int J Gynecol Obstet 2016;132:252-258.

7. Owens G, Kitchener H. Premalignant disease in the genital tract in pregnancy. Best Pract Res Clin Obstet Gynaecol 2016;33:33-43.

8. Trottier H, et al. Risk of human papillomavirus infection and cervical neoplasia after pregnancy. BMC pregnancy childbirth 2015;144(15):1-7.

9. Committee on Practice Bulletins. Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012; 120:964.

10. The Apgar score, Committee Opinion. Obstet Gynecol 2015;644:1-4.

11. Serati M, et al. Natural History of cervical intraepithelial dysplasia during pregnancy. Acta Obstet Gynecol Scand 2008; 87(12):1296-300.

12. Bentley J, et al. Colposcopic Management of abnormal cervical cytology and histology. J Obstet Gynaecol Can 2012; 34 (12): 1188-1202.

13. Mazzoni S, Bienenfeld S, Krull M, Mets T, Alston J. Perinatal high-grade cervical citology: a case series from safety net institution. J Lower Gen Tract dis 2015; 19(4):329-332.

14. Massad L, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013 121(4): 829-46.

15. Shanbhag S, Clark H, Timmaraju V, Bhattacharya S, Cruickshank M. Pregnancy outcome after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2009;114(4):727- 35.